MX2020011247A - Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9). - Google Patents

Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9).

Info

Publication number
MX2020011247A
MX2020011247A MX2020011247A MX2020011247A MX2020011247A MX 2020011247 A MX2020011247 A MX 2020011247A MX 2020011247 A MX2020011247 A MX 2020011247A MX 2020011247 A MX2020011247 A MX 2020011247A MX 2020011247 A MX2020011247 A MX 2020011247A
Authority
MX
Mexico
Prior art keywords
release formulation
local delivery
sustained release
cdk9 inhibitors
cdk9
Prior art date
Application number
MX2020011247A
Other languages
English (en)
Inventor
Dominik R Haudenschild
Jasper H N Yik
Jamal S Lewis
Tom Yarbrough
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of MX2020011247A publication Critical patent/MX2020011247A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

La presente invención describe una nueva formulación de liberación sostenida para la administración local de inhibidores de CDK9.
MX2020011247A 2018-04-23 2019-04-23 Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9). MX2020011247A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862661599P 2018-04-23 2018-04-23
PCT/US2019/028721 WO2019209825A1 (en) 2018-04-23 2019-04-23 Sustained release formulation for local delivery of cdk9 inhibitors

Publications (1)

Publication Number Publication Date
MX2020011247A true MX2020011247A (es) 2021-02-18

Family

ID=68295775

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011247A MX2020011247A (es) 2018-04-23 2019-04-23 Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9).

Country Status (9)

Country Link
US (1) US20220175750A1 (es)
EP (1) EP3784291A4 (es)
JP (1) JP7417958B2 (es)
KR (1) KR20210021452A (es)
CN (1) CN112566673A (es)
AU (1) AU2019257680A1 (es)
CA (1) CA3098129A1 (es)
MX (1) MX2020011247A (es)
WO (1) WO2019209825A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024040154A2 (en) * 2022-08-17 2024-02-22 The Regents Of The University Of California Inhalable compositions of cdk9 inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8043631B2 (en) * 2004-04-02 2011-10-25 Au Jessie L S Tumor targeting drug-loaded particles
US20060046960A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
EP2436376B1 (en) * 2007-09-28 2014-07-09 BIND Therapeutics, Inc. Cancer cell targeting using nanoparticles
EP2309990B2 (en) * 2008-06-16 2017-03-15 Pfizer Inc. Drug loaded polymeric nanoparticles and methods of making and using same
EP2971010B1 (en) * 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20180200279A1 (en) * 2014-07-31 2018-07-19 Xavier University Of Louisiana Inhibition of hsv-1-associated corneal neovascularization using inhibitors of cyclin-dependent kinase 9
WO2016123352A1 (en) * 2015-01-28 2016-08-04 Allergan, Inc. Joint fat pad formulations, and methods of use thereof

Also Published As

Publication number Publication date
CA3098129A1 (en) 2019-10-31
KR20210021452A (ko) 2021-02-26
EP3784291A4 (en) 2022-01-26
WO2019209825A1 (en) 2019-10-31
EP3784291A1 (en) 2021-03-03
US20220175750A1 (en) 2022-06-09
JP7417958B2 (ja) 2024-01-19
AU2019257680A1 (en) 2020-12-03
JP2021522343A (ja) 2021-08-30
CN112566673A (zh) 2021-03-26

Similar Documents

Publication Publication Date Title
MX2020004084A (es) Agentes farmaceuticos como inhibidores del rsv para utilizar en combinacion.
NZ763551A (en) Compounds useful for inhibiting cdk7
CA211013S (en) Vaporizer device
MX2020003421A (es) Metodos para la administracion de ciertos inhibidores del transportador vesicular de monoamina 2 (vmat2).
MX2018006150A (es) Moduladores de receptores de quimiocina.
GEP20227403B (en) Compounds
PH12016502255A1 (en) Combination
UY38837A (es) Proceso de elaboración de moduladores de cftr
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
MA39749A (fr) Dérivés de pipéridine-dione
CR20210297A (es) Derivados de amidas policiclicas como inhibidores de cdk9 (divisional exp. 2017-596)
ZA201708234B (en) Delivery systems for controlled drug release
MX2019010642A (es) Inhibidores de cinasa activada por mitogeno 2 (mk2), sintesis de los mismos, e intermediarios de los mismos.
PH12018500282A1 (en) Cgrp receptor antagonists
CA185542S (en) Table
MX2020003439A (es) Compuestos biciclicos para usarse como inhibidores de cinasa de la proteina 1 de interaccion con receptores (rip1).
MX2020014097A (es) Lipidos novedosos.
MX2020003706A (es) Aminoimidazopiridazinas como inhibidores de cinasa.
MX2020004424A (es) Formulacion aerosolizable.
TN2018000057A1 (en) Compounds useful for inhibiting ror-gamma-t.
GEP20237503B (en) Novel pharmaceutical formulation comprising dual nk-1/nk-3 receptor antagonists
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2020011247A (es) Formulaciones de liberacion sostenida para el suministro local de inhibidores de la cinasa 9 dependiente de ciclina (cdk9).
MX2018010652A (es) Composiciones farmaceuticas.
SA119400353B1 (ar) مشتق بيرازول مستبدل